The scientist-to-biotech-founder transition is one of the most consequential career pivots in the life sciences, and it’s consistently underestimated by the people making it. You don’t just add business tasks to your scientific workload. You change the fundamental unit of your professional output, the way you make decisions, and the metrics by which your work gets judged. This guide maps the specific competencies you need to build, the decisions that carry the highest early-stage risk, and the sequence that gives you the best chance of getting through the first 18 months without a costly structural mistake.
Key Takeaways
- File a provisional patent application before any public disclosure of your science
- Build financial literacy around burn rate, runway, and dilution before your first funding conversation
- Pursue non-dilutive funding (EIC Pathfinder, Innovate UK) before approaching equity investors
- Understand your institution’s IP ownership position before incorporating
- The CEO-vs-CSO decision becomes urgent at Series A, not at founding
- Hire to cover your competency gaps, not to replicate your scientific strengths
The Founding Transition Is a Role Change, Not a Title Change
Founding a biotech company requires a structural shift in how you allocate attention, make decisions, and define progress. Scientists are trained to accumulate evidence before acting. Founders must act on incomplete data routinely, because the cost of waiting for certainty is often higher than the cost of a correctable mistake.
Your primary output changes. As a scientist, you produce publishable results, grant reports, and peer-reviewed contributions. As a founder, you produce company-building milestones: a signed licensing agreement, a funded seed round, a regulatory pre-submission meeting. Those two output types can directly conflict. Presenting your data at a conference before filing a patent application is a textbook example of scientific progress undermining commercial value.
Accountability expands in scope. You’re no longer responsible for your own research programme. You’re responsible for a cap table, a team’s salaries, and eventually a board with its own definition of what progress looks like. That shift is disorienting when scientific credibility has been your primary professional currency for a decade or more.
What Must a Scientist Learn to Become a Biotech Founder?
The five competency domains below represent the minimum viable knowledge set for a scientist-founder in the first six months. They’re listed in the order you should acquire them, not in order of difficulty.
- IP strategy and patent mechanics — freedom-to-operate analysis, provisional vs. full applications, publication timing
- Company-level financial literacy — burn rate, runway calculation, dilution mechanics, cap table structure
- Regulatory pathway literacy — Clinical Trial Application (CTA) and Marketing Authorisation Application (MAA) in the EU/UK, IND and NDA in the US, CE marking for devices
- Funding instrument mechanics — SAFE notes, convertible notes, non-dilutive grants, venture studio structures
- Team-building and leadership — co-founder selection, advisory board construction, equity split principles
IP Protection Before You Can Talk About the Science
What is a provisional patent application? A provisional patent application is a lower-cost filing with a patent office that establishes a priority date for your invention without requiring full claims. It gives you 12 months to develop the technology, raise funding, and prepare a full application, while protecting your right to the filing date if a competitor files later.
The single most common early-stage mistake is presenting scientific results at a conference, or submitting a paper, before filing any patent application. Public disclosure starts a 12-month grace period in the US but eliminates patent rights entirely in most other jurisdictions, including many European markets. If your target commercial territory includes the EU, disclosure before filing is not a recoverable error.
Work with your technology transfer office (TTO) or an independent patent attorney to file a provisional application before any external presentation of your data. Then schedule a 30-minute call with a biotech-specialist IP lawyer to understand the difference between IP assignment and IP licensing from your institution. Most university spin-outs involve a licensing agreement where the institution retains ownership and grants you commercial rights. The terms of that agreement, including royalty rates, sublicensing rights, and milestone payments, shape your company’s commercial position for years. Sign nothing before you understand what you’re agreeing to.
Freedom-to-operate (FTO) analysis, which assesses whether your product or process infringes existing third-party patents, is a separate exercise from your own filing strategy. You need both. Investors at seed stage will ask about FTO. Not having an answer signals a gap in commercial readiness.
Funding Structures in the UK and European Ecosystem
What is non-dilutive funding? Non-dilutive funding is capital provided to a company that does not require the founder to give up equity. Grants, innovation awards, and certain loan instruments are non-dilutive, meaning your ownership percentage stays intact after receiving the funds.
Non-dilutive funding should be your first port of call. The EIC Pathfinder grant, part of the European Innovation Council’s Horizon Europe programme, targets early-stage deep tech and life sciences projects and provides capital without equity dilution. Innovate UK Smart Grants serve a similar function for UK-based companies. Both add credibility to subsequent investor conversations because they represent independent technical validation.
| Funding Instrument | Type | Dilutive? | Geography |
|---|---|---|---|
| EIC Pathfinder | Grant | No | EU / Associated Countries |
| Innovate UK Smart Grant | Grant | No | UK |
| SAFE Note | Equity instrument | Yes (deferred) | Any |
| Venture Studio | Co-founding equity | Yes | Any |
SAFE notes, Simple Agreements for Future Equity, allow early-stage companies to raise capital from angel investors without setting a company valuation at the time of investment. This is useful when your science is too early for a defensible Series A valuation but you need runway to reach the next data milestone. A SAFE with a low valuation cap can, however, significantly dilute founders at Series A if the company’s value has grown substantially between rounds. Model the dilution scenarios before you sign.
Venture studios are an underused option for scientist-founders who want to retain scientific focus. A studio co-founds the company and provides operational infrastructure, including commercial development, regulatory affairs support, and financial management, in exchange for a founding equity stake. The trade-off is clear: you give up a larger equity share early, but you gain operational capability you’d otherwise need to hire or learn yourself.
The CEO-vs-CSO Decision: When It Becomes Urgent
Most scientific founders begin as CEO because no one else has the scientific depth to represent the company credibly to early investors and partners. That’s rational. The science is the asset, and you’re the person who can explain it with authority. Staying as CEO in the pre-seed and seed stage is often the right call.
The decision becomes urgent at Series A, or when the company needs to run parallel workstreams, such as clinical operations, business development, and regulatory affairs, that exceed what a scientist-CEO can manage without sacrificing scientific oversight. The trigger is usually investor pressure combined with a specific operational gap, not a general sense that you’re “not a business person.”
Transitioning to CSO is not a demotion. Companies where the founding scientist retains the CSO role and an experienced CEO handles commercial operations often outperform those where the founder tries to scale into a full commercial CEO role without the relevant background. The honest question to ask yourself is whether your time produces more value at the bench and in scientific advisory conversations, or in investor relations and operational management. The answer is usually the former.
Building Your Founding Team Around Gaps, Not Strengths
Scientist-founders tend to recruit people who are scientifically similar to themselves. The first hires should do the opposite. A co-founder with commercial development, regulatory affairs, or financial management experience is more valuable at founding than a second scientist, even when the science is the company’s core asset.
Map your current network against three archetypes: scientific co-founder, business co-founder, and clinical or regulatory advisor. Identify which gaps need filling within 90 days of founding. Advisors with specific domain expertise, including regulatory strategy, IP litigation, and clinical operations, provide high-value input at low cost in the early stage. Build your scientific advisory board before you need it, not after a problem surfaces that you can’t solve internally.
Your 18-Month Transition Roadmap
The founding period is defined by decisions that constrain future options, not by scientific progress alone. The sequence matters.
- Months 0–3: IP disclosure to TTO, provisional patent filing, institutional licensing agreement negotiation, company incorporation
- Months 1–4: Non-dilutive funding applications (EIC, Innovate UK), advisory board recruitment, co-founder identification
- Months 3–9: Seed fundraise (SAFE or equity round), regulatory pre-submission meeting with EMA or MHRA, first hire
- Months 9–18: Series A preparation, CEO-vs-CSO assessment, clinical strategy finalisation
Scientist-founders who manage this transition most effectively treat commercial and legal competency-building with the same rigour they applied to their doctoral training: systematically, with expert input, and without assuming prior knowledge is sufficient. The science got you to the founding moment. The competencies above determine what happens next.
Use the EFB Public Biotech Salary Estimator to benchmark founding team compensation as you build your cap table, and explore the clinical trial tools for translational planning context as you frame your regulatory timeline for investors.
Frequently Asked Questions
When should I file a patent before starting a biotech company?
You should file a provisional patent application before any public disclosure of your science, including conference presentations and paper submissions. In most European jurisdictions, public disclosure before filing eliminates patent rights entirely. Filing a provisional establishes a priority date at lower cost and gives you 12 months to prepare a full application.
How do I find a business co-founder for my biotech startup?
Start with your technology transfer office’s network, biotech cluster events at hubs like Babraham Research Campus or Stevenage Bioscience Catalyst, and founder communities such as the EBF network. Look for candidates with regulatory affairs, business development, or financial management backgrounds rather than scientific backgrounds similar to your own.
What grants are available for biotech startups in Europe?
The EIC Pathfinder and EIC Accelerator programmes under Horizon Europe are the primary non-dilutive options for EU-based or associated-country founders. UK-based founders should assess Innovate UK Smart Grants and UKRI funding streams. Wellcome Leap programmes also fund early-stage translational work in specific therapeutic areas.
Should a scientist stay as CEO of their biotech company?
In the pre-seed and seed stage, yes. Scientific credibility is your primary investor-facing asset at this stage. The decision to bring in a professional CEO typically becomes urgent at Series A, when operational complexity exceeds what a scientist-CEO can manage alongside scientific leadership responsibilities.
What is the difference between a CTA and an IND for biotech founders?
A Clinical Trial Application (CTA) is the regulatory submission required to initiate a clinical trial in the EU or UK, submitted to the relevant national competent authority under EMA oversight. An Investigational New Drug (IND) application serves the equivalent function in the US, submitted to the FDA. The data packages, timelines, and fee structures differ between jurisdictions, so your regulatory strategy should reflect your target market from the outset.
